Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 22

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 22
---
 our product candidates. If we encounter difficulties enrolling patients in our clinical trials, 
 our clinical development activities could be delayed or otherwise adversely affected.                                                  |

| ● | we face competition from                                                                                                                  
 companies that have developed or may develop product candidates for the treatment of the diseases that we may target, including companies 
 developing novel therapies and platform technologies. If these companies develop platform technologies or product candidates more         
 rapidly than we do, if their platform technologies or product candidates are more effective or have fewer side effects, our ability       
 to develop and successfully commercialize product candidates may be adversely affected.                                                   |

| ● | we operate in a rapidly                                                                                                            
 changing industry and face significant competition, which may result in others discovering, developing or commercializing products 
 before or more successfully than we do.                                                                                            |

| ● | we are highly dependent                                                                                                                
 on our key personnel, including individuals with expertise in cell therapy development and manufacturing, and if we are not successful 
 in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.            |

| ● | we will need substantial                                                                                                                     
 additional financing to develop our products and implement our operating plans, which financing we may be unable to obtain, or unable        
 to obtain on acceptable terms. If we fail to obtain additional financing, we may be unable to complete the development and commercialization 
 of our product candidates.                                                                                                                   |

| ● | we maintain single supply                                                                                                        
 relationships for certain key components, and our business and operating results could be harmed if supply is restricted or ends 
 or the price of raw materials used in our suppliers’ manufacturing process increases.                                            |

| ● | regulatory requirements                                                                                                            
 in the United States and abroad governing cell therapy products have changed frequently and may continue to change in the future,  
 which could negatively impact our ability to complete clinical trials and commercialize our product candidates in a timely manner, 
 if at all.                                                                                                                         |

| ● | our intellectual property                                                                                          
 rights are valuable, and any inability to protect them could reduce the value of our products, services and brand. |

| ● | an active trading market                                                                                                          
 for our Common Stock may not be available on a consistent basis to provide stockholders with adequate liquidity. The price of our 
 Common Stock may be extremely volatile, and stockholders could lose all or part of their investment.                              |

| ● | our failure to meet the                                                                 
 continued listing requirements of Nasdaq could result in a delisting of our securities. |

| ● | since the completion of